Review



rabbit anti human ps6 primary antibody  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc rabbit anti human ps6 primary antibody
    Rabbit Anti Human Ps6 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 169 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Rabbit+mAb/pm41402283-340-0-5
    Average 95 stars, based on 169 article reviews
    rabbit anti human ps6 primary antibody - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: A bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model.
    Article Snippet: Sections were incubated in primary antibody, anti-pS6 (1:500; Cell Signaling Technology; Ser 240/244, 61H9, #4838), in 0.1% Tween-20 and 2% BSA in PBS overnight at 4 °C.



    Similar Products

    95
    Cell Signaling Technology Inc rabbit anti human ps6 primary antibody
    Rabbit Anti Human Ps6 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Rabbit+mAb/pm41402283-340-0-5
    Average 95 stars, based on 1 article reviews
    rabbit anti human ps6 primary antibody - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc primary antibody anti-ps6
    Primary Antibody Anti Ps6, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/anti+ps1/pm40594897-232-6-8
    Average 90 stars, based on 1 article reviews
    primary antibody anti-ps6 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc primary antibodies against ps6 240 244
    a , Representative hematoxylin and eosin (HE) staining of 20μm-thick frozen brain sections showing dysmorphic neurons (DN, empty arrowheads) and balloon cells (BC, filled arrowheads) across FCDII patients (n = 1 section/patient). Scale bar: 100μm. Insets for patients pt6, pt7 and pt10 show a representative BC from distinct cortical regions. b , Immunohistochemical detection of mTOR pathway activation using <t>phosphorylated</t> <t>S6</t> <t>(pS6-Ser240/244)</t> antibody on 4μm-thick formalin-fixed paraffin-embedded (FFPE) brain sections (n = 1 section/patient). DN (empty arrowheads) and BC (filled arrowheads) exhibit strong pS6 immunoreactivity. Scale bar: 50μm. Insets for patients pt7-9 show representative DN from distinct cortical regions. c , Quantification of grey and white matter proportions in 20μm-thick HE-stained frozen brain sections adjacent to tissue used for single-nucleus RNA sequencing (n = 1 section/patient).
    Primary Antibodies Against Ps6 240 244, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser240%2F244)+XP+Rabbit+mAb/pmc12081288-216-4-10
    Average 96 stars, based on 1 article reviews
    primary antibodies against ps6 240 244 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti ps6 primary antibody
    a , Representative hematoxylin and eosin (HE) staining of 20μm-thick frozen brain sections showing dysmorphic neurons (DN, empty arrowheads) and balloon cells (BC, filled arrowheads) across FCDII patients (n = 1 section/patient). Scale bar: 100μm. Insets for patients pt6, pt7 and pt10 show a representative BC from distinct cortical regions. b , Immunohistochemical detection of mTOR pathway activation using <t>phosphorylated</t> <t>S6</t> <t>(pS6-Ser240/244)</t> antibody on 4μm-thick formalin-fixed paraffin-embedded (FFPE) brain sections (n = 1 section/patient). DN (empty arrowheads) and BC (filled arrowheads) exhibit strong pS6 immunoreactivity. Scale bar: 50μm. Insets for patients pt7-9 show representative DN from distinct cortical regions. c , Quantification of grey and white matter proportions in 20μm-thick HE-stained frozen brain sections adjacent to tissue used for single-nucleus RNA sequencing (n = 1 section/patient).
    Anti Ps6 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Antibody/pm39303528-88-33-37
    Average 96 stars, based on 1 article reviews
    anti ps6 primary antibody - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc ps6 primary cell signalling technology
    a , Representative hematoxylin and eosin (HE) staining of 20μm-thick frozen brain sections showing dysmorphic neurons (DN, empty arrowheads) and balloon cells (BC, filled arrowheads) across FCDII patients (n = 1 section/patient). Scale bar: 100μm. Insets for patients pt6, pt7 and pt10 show a representative BC from distinct cortical regions. b , Immunohistochemical detection of mTOR pathway activation using <t>phosphorylated</t> <t>S6</t> <t>(pS6-Ser240/244)</t> antibody on 4μm-thick formalin-fixed paraffin-embedded (FFPE) brain sections (n = 1 section/patient). DN (empty arrowheads) and BC (filled arrowheads) exhibit strong pS6 immunoreactivity. Scale bar: 50μm. Insets for patients pt7-9 show representative DN from distinct cortical regions. c , Quantification of grey and white matter proportions in 20μm-thick HE-stained frozen brain sections adjacent to tissue used for single-nucleus RNA sequencing (n = 1 section/patient).
    Ps6 Primary Cell Signalling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Antibody/pm38750012-293-75-77
    Average 96 stars, based on 1 article reviews
    ps6 primary cell signalling technology - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti ps6 primary antibody
    AMPK signaling upon short salsalate treatment in PKD animals (A) Western blotting for pAMPK and AMPK on protein extracts isolated from wildtype, PKD and PKD + SAL kidneys. β-actin protein expression was used as an internal loading control. (B) Quantification of the pAMPK and AMPK blots shown in (A), relative to β-actin. Both pAMPK and AMPK expression is increased in PKD + SAL animals, compared to PKD, resulting in a non-significant difference in the pAMPK/AMPK ratio. (C) Western blotting for pACC, ACC, and PGC1α on protein extracts isolated from wildtype, PKD, and PKD + SAL kidneys. Tubulin protein expression was used as an internal loading control. Please note that for the PGC1α blot, only the lower band visible corresponds to the PGC1α protein. (D) Quantification of the pACC, ACC, and PGC1α blots shown in (C), relative to tubulin. pACC expression is increased significantly in PKD + SAL animals, compared to PKD, while ACC expression is trending toward a significant increase (p = 0.0614). This results in a non-significant difference in the pACC/ACC ratio. PGC1α expression is reduced in PKD animals, which is attenuated by short salsalate treatment. (E) Western blotting for <t>pS6,</t> S6, and p-p70S6K on protein extracts isolated from wildtype, PKD, and PKD + SAL kidneys. β-actin and tubulin protein expression were used as an internal loading control. (F) Quantification of the pS6, S6, and p-p70S6K blots shown in (E), relative to β-actin (pS6, S6) and tubulin (p-p70S6K). No significant differences were detected between wildtype, PKD, and PKD + SAL animals. Each dot represents a mouse kidney (n = 3–4 animals per group). Data presented are mean ± SD. ∗p < 0.05, ∗∗p < 0.01, measured by two-way unpaired Student’s t tests. M = marker, MW = molecular weight, WT = wildtype, SAL = Salsalate, kDa = kilodalton.
    Rabbit Anti Ps6 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser240%2F244)+Antibody/pmc10665819-93-0-5
    Average 96 stars, based on 1 article reviews
    rabbit anti ps6 primary antibody - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc ps6 primary ab
    a . Comparison of feature embedding methodologies (CP-DINO 1640 with and without <t>pS6</t> information) based on median AUC of binary classification of KO from WT for each genetic perturbation. b . Top neighbor genes to mTOR and TSC2 (mTORC1 activator and inhibitor respectively) predicted with and without pS6 are shown. Numbers indicate cosine similarity. c . the pipeline for conducting single-cell based analysis via Kolmogorov-Smirnov 2-sided, 2-tailed statistical test with benjamini-hochberg correction, in contrast to methods used for flow-based screens such as MAUDE . d . results of single-cell based, one-feature analysis of cytoplasmic <t>phospho-S6.</t> Teal genes are well established mTOR upregulators, orange genes are well established mTOR downregulators, black genes are potentially novel pS6 modifiers. e . representative pS6 field with segmentation. f . example pS6 and mitoprobe staining images from control, known, and potentially novel regulators of mTORC1. g-h . differential feature analysis on AURKAIP1 and HSD17B10 .
    Ps6 Primary Ab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Antibody/bio_rxiv__2023__08__13__553051-287-14-5
    Average 96 stars, based on 1 article reviews
    ps6 primary ab - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti-ps6 mouse primary
    a . Comparison of feature embedding methodologies (CP-DINO 1640 with and without <t>pS6</t> information) based on median AUC of binary classification of KO from WT for each genetic perturbation. b . Top neighbor genes to mTOR and TSC2 (mTORC1 activator and inhibitor respectively) predicted with and without pS6 are shown. Numbers indicate cosine similarity. c . the pipeline for conducting single-cell based analysis via Kolmogorov-Smirnov 2-sided, 2-tailed statistical test with benjamini-hochberg correction, in contrast to methods used for flow-based screens such as MAUDE . d . results of single-cell based, one-feature analysis of cytoplasmic <t>phospho-S6.</t> Teal genes are well established mTOR upregulators, orange genes are well established mTOR downregulators, black genes are potentially novel pS6 modifiers. e . representative pS6 field with segmentation. f . example pS6 and mitoprobe staining images from control, known, and potentially novel regulators of mTORC1. g-h . differential feature analysis on AURKAIP1 and HSD17B10 .
    Anti Ps6 Mouse Primary, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibody+anti-ps6/Phospho-S6+Ribosomal+Protein+(Ser235%2F236)+Antibody/ppr0659027-89-7-14
    Average 96 stars, based on 1 article reviews
    anti-ps6 mouse primary - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    a , Representative hematoxylin and eosin (HE) staining of 20μm-thick frozen brain sections showing dysmorphic neurons (DN, empty arrowheads) and balloon cells (BC, filled arrowheads) across FCDII patients (n = 1 section/patient). Scale bar: 100μm. Insets for patients pt6, pt7 and pt10 show a representative BC from distinct cortical regions. b , Immunohistochemical detection of mTOR pathway activation using phosphorylated S6 (pS6-Ser240/244) antibody on 4μm-thick formalin-fixed paraffin-embedded (FFPE) brain sections (n = 1 section/patient). DN (empty arrowheads) and BC (filled arrowheads) exhibit strong pS6 immunoreactivity. Scale bar: 50μm. Insets for patients pt7-9 show representative DN from distinct cortical regions. c , Quantification of grey and white matter proportions in 20μm-thick HE-stained frozen brain sections adjacent to tissue used for single-nucleus RNA sequencing (n = 1 section/patient).

    Journal: Nature Neuroscience

    Article Title: Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia

    doi: 10.1038/s41593-025-01936-z

    Figure Lengend Snippet: a , Representative hematoxylin and eosin (HE) staining of 20μm-thick frozen brain sections showing dysmorphic neurons (DN, empty arrowheads) and balloon cells (BC, filled arrowheads) across FCDII patients (n = 1 section/patient). Scale bar: 100μm. Insets for patients pt6, pt7 and pt10 show a representative BC from distinct cortical regions. b , Immunohistochemical detection of mTOR pathway activation using phosphorylated S6 (pS6-Ser240/244) antibody on 4μm-thick formalin-fixed paraffin-embedded (FFPE) brain sections (n = 1 section/patient). DN (empty arrowheads) and BC (filled arrowheads) exhibit strong pS6 immunoreactivity. Scale bar: 50μm. Insets for patients pt7-9 show representative DN from distinct cortical regions. c , Quantification of grey and white matter proportions in 20μm-thick HE-stained frozen brain sections adjacent to tissue used for single-nucleus RNA sequencing (n = 1 section/patient).

    Article Snippet: Co-immunofluorescence was performed using primary antibodies against pS6 240/244 (1:1,000, Cell Signaling, cat. no. 5364), VIM (1:100, Dako, cat. no. M0725), SMI311 (1:500, BioLegend, cat. no. 837801), GFAP (1:200, Thermo Fisher Scientific, cat. no. MA5-15086), NRGN (1:50, Thermo Fisher Scientific, cat. no. PA5-19209), OLIG2 (1:100, R&D Systems, cat. no. AF2418), IBA1 (1:500, Abcam, cat. no. ab5076), NEUN (1:500, Millipore, cat. no. MAB377) and VDAC1 (1:500, Abcam, cat. no. ab16814).

    Techniques: Staining, Immunohistochemical staining, Activation Assay, Formalin-fixed Paraffin-Embedded, RNA Sequencing

    a , Distribution of 808 genotyped nuclei in UMAP space: 117 were classified as Mut. (pt10 = 89, pt9 = 25, pt7 = 2, pt6 = 1) or as Ref. Right, Mut. nuclei percentages per cell type (top) and across cell types (bottom). b , Representative images of co-immunofluorescence staining on formalin-fixed paraffin-embedded sections ( n = 1 per patient) showing mTOR-hyperactive (pS6 + ) neurons (NEUN + , pt2), astrocytes (GFAP + , pt2), oligodendrocytes (OLIG2 + , pt2) and microglia (IBA1 + , pt10). Nuclei (in blue) are labeled with DAPI. Scale bars, 20 µm. All patients included in this experiment are detailed in Supplementary Table . c , Cytomegalic cells representing a minor fraction of mutated cells. Left, representative immunostaining of SMI311 + DNs and VIM + BCs on frozen brain tissue from pt5. Nuclei (in blue) are labeled with DAPI for total cell counting. Scale bar, 25 µm. Right, mutated cell percentage (inferred by the detected VAF) and proportion of DNs or BCs identified in each patient ( n = 1 section/patient/staining was analyzed). d , Schematic of the distribution of mutated cells across cell types and the fraction of mutated cytomegalic cells in pt10. Astro, astrocytes; Endo, endothelial cells; Hemi, hemispherical; Oligo, oligodendrocytes; Micro, microglia.

    Journal: Nature Neuroscience

    Article Title: Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia

    doi: 10.1038/s41593-025-01936-z

    Figure Lengend Snippet: a , Distribution of 808 genotyped nuclei in UMAP space: 117 were classified as Mut. (pt10 = 89, pt9 = 25, pt7 = 2, pt6 = 1) or as Ref. Right, Mut. nuclei percentages per cell type (top) and across cell types (bottom). b , Representative images of co-immunofluorescence staining on formalin-fixed paraffin-embedded sections ( n = 1 per patient) showing mTOR-hyperactive (pS6 + ) neurons (NEUN + , pt2), astrocytes (GFAP + , pt2), oligodendrocytes (OLIG2 + , pt2) and microglia (IBA1 + , pt10). Nuclei (in blue) are labeled with DAPI. Scale bars, 20 µm. All patients included in this experiment are detailed in Supplementary Table . c , Cytomegalic cells representing a minor fraction of mutated cells. Left, representative immunostaining of SMI311 + DNs and VIM + BCs on frozen brain tissue from pt5. Nuclei (in blue) are labeled with DAPI for total cell counting. Scale bar, 25 µm. Right, mutated cell percentage (inferred by the detected VAF) and proportion of DNs or BCs identified in each patient ( n = 1 section/patient/staining was analyzed). d , Schematic of the distribution of mutated cells across cell types and the fraction of mutated cytomegalic cells in pt10. Astro, astrocytes; Endo, endothelial cells; Hemi, hemispherical; Oligo, oligodendrocytes; Micro, microglia.

    Article Snippet: Co-immunofluorescence was performed using primary antibodies against pS6 240/244 (1:1,000, Cell Signaling, cat. no. 5364), VIM (1:100, Dako, cat. no. M0725), SMI311 (1:500, BioLegend, cat. no. 837801), GFAP (1:200, Thermo Fisher Scientific, cat. no. MA5-15086), NRGN (1:50, Thermo Fisher Scientific, cat. no. PA5-19209), OLIG2 (1:100, R&D Systems, cat. no. AF2418), IBA1 (1:500, Abcam, cat. no. ab5076), NEUN (1:500, Millipore, cat. no. MAB377) and VDAC1 (1:500, Abcam, cat. no. ab16814).

    Techniques: Immunofluorescence, Staining, Formalin-fixed Paraffin-Embedded, Labeling, Immunostaining, Cell Counting

    a , Left, LCM–seq workflow for capturing pools of DNs, BCs and NNs from eight patients (pt1–5 and pt7–9). Right, heatmap of NEFM and VIM normalized expression with unsupervised hierarchical clustering. b , Label transfer of LCM–seq samples on to the snRNA-seq UMAP space showing NNs or DNs matching with GluNs and BCs with astrocytes. c , Left, NRGN and GFAP normalized expression heatmap with unsupervised hierarchical clustering. Right, co-immunofluorescence showing NRGN in pS6 + /SMI311 + DNs and GFAP in pS6 + /VIM + BCs (pt5) ( n = 1 section/patient/staining analyzed). GFAP-pS6 and VIM-pS6 double stainings were performed on two consecutive sections and the same BC was recognized in both sections. Nuclei (in blue) are labeled with DAPI. Scale bars, 50 µm. d , Visium spatial transcriptomics showing intermingled spots containing DNs and BCs across the tissue (pt5). Magnified images show representative DN- and BC-containing spots after hematoxylin and eosin staining ( n = 1 section per patient analyzed). Scale bars, 1.5 mm; insets = 55 µm. e , Top markers of DN- and BC-containing spots (pt5). Known histological markers for DNs ( NEFM ) and BCs ( CRYAB ) are enriched in spots with DNs and BCs. f , Spatial semi-supervised clustering of Visium spots showing clusters enriched in GluNs, astrocytes and oligodendrocytes (pt5) with top marker genes in parentheses. g , Distinct clusters for DNs, BCs, astrocytes (Astros) and GluNs from single cells (pt5 and pt9) of the MERSCOPE UMAP space. h , Heatmap of the top ten DN or BC markers with representative MERSCOPE images (pt5). DNs are identified as pS6 + /NEUN + and BCs as pS6 + /NEUN − ( n = 1 section per patient analyzed). Scale bars, 50 µm. i , Left, number of shared dysregulated genes across Mut. versus Ref. GluNs (snRNA-seq), DNs versus NNs (LCM–seq) and DN-containing spots (Visium). Right, top GO terms of DN upregulated genes. Ribo-nt., ribonucleotides; metab., metabolic; proc., process; Ribo-ns., ribonucleosides; RP., ribosomal proteins; rNTP, ribonucleoside triphosphates. j , Representative images of strong VDAC1 immunostaining in pS6 + DNs (pt2) ( n = 1 section/patient/staining analyzed). Scale bars, 50 µm. k , Electron microscopy of DNs (pt5) showing an accumulation of vesicular, swollen, damaged mitochondria (black circles) ( n = 1 section per patient analyzed). Scale bar, 2.5 µm. Detailed sample information for each experiment and analysis is provided in Supplementary Table . expr., expression; max., maximum; min., minimum.

    Journal: Nature Neuroscience

    Article Title: Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia

    doi: 10.1038/s41593-025-01936-z

    Figure Lengend Snippet: a , Left, LCM–seq workflow for capturing pools of DNs, BCs and NNs from eight patients (pt1–5 and pt7–9). Right, heatmap of NEFM and VIM normalized expression with unsupervised hierarchical clustering. b , Label transfer of LCM–seq samples on to the snRNA-seq UMAP space showing NNs or DNs matching with GluNs and BCs with astrocytes. c , Left, NRGN and GFAP normalized expression heatmap with unsupervised hierarchical clustering. Right, co-immunofluorescence showing NRGN in pS6 + /SMI311 + DNs and GFAP in pS6 + /VIM + BCs (pt5) ( n = 1 section/patient/staining analyzed). GFAP-pS6 and VIM-pS6 double stainings were performed on two consecutive sections and the same BC was recognized in both sections. Nuclei (in blue) are labeled with DAPI. Scale bars, 50 µm. d , Visium spatial transcriptomics showing intermingled spots containing DNs and BCs across the tissue (pt5). Magnified images show representative DN- and BC-containing spots after hematoxylin and eosin staining ( n = 1 section per patient analyzed). Scale bars, 1.5 mm; insets = 55 µm. e , Top markers of DN- and BC-containing spots (pt5). Known histological markers for DNs ( NEFM ) and BCs ( CRYAB ) are enriched in spots with DNs and BCs. f , Spatial semi-supervised clustering of Visium spots showing clusters enriched in GluNs, astrocytes and oligodendrocytes (pt5) with top marker genes in parentheses. g , Distinct clusters for DNs, BCs, astrocytes (Astros) and GluNs from single cells (pt5 and pt9) of the MERSCOPE UMAP space. h , Heatmap of the top ten DN or BC markers with representative MERSCOPE images (pt5). DNs are identified as pS6 + /NEUN + and BCs as pS6 + /NEUN − ( n = 1 section per patient analyzed). Scale bars, 50 µm. i , Left, number of shared dysregulated genes across Mut. versus Ref. GluNs (snRNA-seq), DNs versus NNs (LCM–seq) and DN-containing spots (Visium). Right, top GO terms of DN upregulated genes. Ribo-nt., ribonucleotides; metab., metabolic; proc., process; Ribo-ns., ribonucleosides; RP., ribosomal proteins; rNTP, ribonucleoside triphosphates. j , Representative images of strong VDAC1 immunostaining in pS6 + DNs (pt2) ( n = 1 section/patient/staining analyzed). Scale bars, 50 µm. k , Electron microscopy of DNs (pt5) showing an accumulation of vesicular, swollen, damaged mitochondria (black circles) ( n = 1 section per patient analyzed). Scale bar, 2.5 µm. Detailed sample information for each experiment and analysis is provided in Supplementary Table . expr., expression; max., maximum; min., minimum.

    Article Snippet: Co-immunofluorescence was performed using primary antibodies against pS6 240/244 (1:1,000, Cell Signaling, cat. no. 5364), VIM (1:100, Dako, cat. no. M0725), SMI311 (1:500, BioLegend, cat. no. 837801), GFAP (1:200, Thermo Fisher Scientific, cat. no. MA5-15086), NRGN (1:50, Thermo Fisher Scientific, cat. no. PA5-19209), OLIG2 (1:100, R&D Systems, cat. no. AF2418), IBA1 (1:500, Abcam, cat. no. ab5076), NEUN (1:500, Millipore, cat. no. MAB377) and VDAC1 (1:500, Abcam, cat. no. ab16814).

    Techniques: Expressing, Immunofluorescence, Staining, Labeling, Marker, Immunostaining, Electron Microscopy

    a , Heatmaps showing normalized (SCTransform) gene expression levels of the 140-gene MERSCOPE panel, grouped by category. Abbreviations: DN, dysmorphic neurons; BC, balloon cells. b , Representative MERSCOPE images of top expressed genes (from Fig. ) in DN (pS6+/NEUN+) and BC (pS6+/NEUN-) from patient pt9 (n = 1 tissue section examined). Yellow puncta indicate individual transcript molecules. Scale bar = 50μm. c , Spatial detection of mitochondrial gene transcripts (yellow puncta) in DN from patients pt5 and pt9 (n = 1 tissue section examined for each patient). Scale bar = 50 μm.

    Journal: Nature Neuroscience

    Article Title: Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia

    doi: 10.1038/s41593-025-01936-z

    Figure Lengend Snippet: a , Heatmaps showing normalized (SCTransform) gene expression levels of the 140-gene MERSCOPE panel, grouped by category. Abbreviations: DN, dysmorphic neurons; BC, balloon cells. b , Representative MERSCOPE images of top expressed genes (from Fig. ) in DN (pS6+/NEUN+) and BC (pS6+/NEUN-) from patient pt9 (n = 1 tissue section examined). Yellow puncta indicate individual transcript molecules. Scale bar = 50μm. c , Spatial detection of mitochondrial gene transcripts (yellow puncta) in DN from patients pt5 and pt9 (n = 1 tissue section examined for each patient). Scale bar = 50 μm.

    Article Snippet: Co-immunofluorescence was performed using primary antibodies against pS6 240/244 (1:1,000, Cell Signaling, cat. no. 5364), VIM (1:100, Dako, cat. no. M0725), SMI311 (1:500, BioLegend, cat. no. 837801), GFAP (1:200, Thermo Fisher Scientific, cat. no. MA5-15086), NRGN (1:50, Thermo Fisher Scientific, cat. no. PA5-19209), OLIG2 (1:100, R&D Systems, cat. no. AF2418), IBA1 (1:500, Abcam, cat. no. ab5076), NEUN (1:500, Millipore, cat. no. MAB377) and VDAC1 (1:500, Abcam, cat. no. ab16814).

    Techniques: Gene Expression

    a , Co-immunofluorescence analysis of VDAC1 (white) and pS6 (pink) across FCDII specimens (patients pt1-10, n = 1 section/patient). Strong VDAC1 signal is observed in dysmorphic neurons (DN, enlarged pS6+ cells, orange arrowheads), while balloon cells (BC, pS6+ cells with glassy cytoplasm, green arrowheads) display weak VDAC1 signal. Inset in pt8 shows representative BC from distinct region. Scale bar = 100 μm. b , Quantitative comparison of VDAC1 expression between DN-positive and DN-negative regions in pt2. Analysis was performed on 0.25 mm² regions of interest (ROIs, n = 4 per condition), showing percentage of VDAC1+ and pS6+ pixels. Two-sided Wilcoxon rank sum exact p-value = 0.02857*. Box plots show median, interquartile range, and min/max values. c , Quantification of VDAC1 expression between DN-positive and BC-positive regions in pt5-8. Analysis was performed on 0.25 mm 2 ROIs (n = 3 per region per patient; total n = 12 per condition). Data shown as percentage of VDAC1+ pixels and pS6+ pixels per ROI. Two-sided Wilcoxon rank sum test, exact p-value = 5.177e-06***. Box plots depict the median and interquartile range, with whiskers indicating minimum and maximum values.

    Journal: Nature Neuroscience

    Article Title: Single-cell genotyping and transcriptomic profiling of mosaic focal cortical dysplasia

    doi: 10.1038/s41593-025-01936-z

    Figure Lengend Snippet: a , Co-immunofluorescence analysis of VDAC1 (white) and pS6 (pink) across FCDII specimens (patients pt1-10, n = 1 section/patient). Strong VDAC1 signal is observed in dysmorphic neurons (DN, enlarged pS6+ cells, orange arrowheads), while balloon cells (BC, pS6+ cells with glassy cytoplasm, green arrowheads) display weak VDAC1 signal. Inset in pt8 shows representative BC from distinct region. Scale bar = 100 μm. b , Quantitative comparison of VDAC1 expression between DN-positive and DN-negative regions in pt2. Analysis was performed on 0.25 mm² regions of interest (ROIs, n = 4 per condition), showing percentage of VDAC1+ and pS6+ pixels. Two-sided Wilcoxon rank sum exact p-value = 0.02857*. Box plots show median, interquartile range, and min/max values. c , Quantification of VDAC1 expression between DN-positive and BC-positive regions in pt5-8. Analysis was performed on 0.25 mm 2 ROIs (n = 3 per region per patient; total n = 12 per condition). Data shown as percentage of VDAC1+ pixels and pS6+ pixels per ROI. Two-sided Wilcoxon rank sum test, exact p-value = 5.177e-06***. Box plots depict the median and interquartile range, with whiskers indicating minimum and maximum values.

    Article Snippet: Co-immunofluorescence was performed using primary antibodies against pS6 240/244 (1:1,000, Cell Signaling, cat. no. 5364), VIM (1:100, Dako, cat. no. M0725), SMI311 (1:500, BioLegend, cat. no. 837801), GFAP (1:200, Thermo Fisher Scientific, cat. no. MA5-15086), NRGN (1:50, Thermo Fisher Scientific, cat. no. PA5-19209), OLIG2 (1:100, R&D Systems, cat. no. AF2418), IBA1 (1:500, Abcam, cat. no. ab5076), NEUN (1:500, Millipore, cat. no. MAB377) and VDAC1 (1:500, Abcam, cat. no. ab16814).

    Techniques: Immunofluorescence, Comparison, Expressing

    AMPK signaling upon short salsalate treatment in PKD animals (A) Western blotting for pAMPK and AMPK on protein extracts isolated from wildtype, PKD and PKD + SAL kidneys. β-actin protein expression was used as an internal loading control. (B) Quantification of the pAMPK and AMPK blots shown in (A), relative to β-actin. Both pAMPK and AMPK expression is increased in PKD + SAL animals, compared to PKD, resulting in a non-significant difference in the pAMPK/AMPK ratio. (C) Western blotting for pACC, ACC, and PGC1α on protein extracts isolated from wildtype, PKD, and PKD + SAL kidneys. Tubulin protein expression was used as an internal loading control. Please note that for the PGC1α blot, only the lower band visible corresponds to the PGC1α protein. (D) Quantification of the pACC, ACC, and PGC1α blots shown in (C), relative to tubulin. pACC expression is increased significantly in PKD + SAL animals, compared to PKD, while ACC expression is trending toward a significant increase (p = 0.0614). This results in a non-significant difference in the pACC/ACC ratio. PGC1α expression is reduced in PKD animals, which is attenuated by short salsalate treatment. (E) Western blotting for pS6, S6, and p-p70S6K on protein extracts isolated from wildtype, PKD, and PKD + SAL kidneys. β-actin and tubulin protein expression were used as an internal loading control. (F) Quantification of the pS6, S6, and p-p70S6K blots shown in (E), relative to β-actin (pS6, S6) and tubulin (p-p70S6K). No significant differences were detected between wildtype, PKD, and PKD + SAL animals. Each dot represents a mouse kidney (n = 3–4 animals per group). Data presented are mean ± SD. ∗p < 0.05, ∗∗p < 0.01, measured by two-way unpaired Student’s t tests. M = marker, MW = molecular weight, WT = wildtype, SAL = Salsalate, kDa = kilodalton.

    Journal: iScience

    Article Title: Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease

    doi: 10.1016/j.isci.2023.108278

    Figure Lengend Snippet: AMPK signaling upon short salsalate treatment in PKD animals (A) Western blotting for pAMPK and AMPK on protein extracts isolated from wildtype, PKD and PKD + SAL kidneys. β-actin protein expression was used as an internal loading control. (B) Quantification of the pAMPK and AMPK blots shown in (A), relative to β-actin. Both pAMPK and AMPK expression is increased in PKD + SAL animals, compared to PKD, resulting in a non-significant difference in the pAMPK/AMPK ratio. (C) Western blotting for pACC, ACC, and PGC1α on protein extracts isolated from wildtype, PKD, and PKD + SAL kidneys. Tubulin protein expression was used as an internal loading control. Please note that for the PGC1α blot, only the lower band visible corresponds to the PGC1α protein. (D) Quantification of the pACC, ACC, and PGC1α blots shown in (C), relative to tubulin. pACC expression is increased significantly in PKD + SAL animals, compared to PKD, while ACC expression is trending toward a significant increase (p = 0.0614). This results in a non-significant difference in the pACC/ACC ratio. PGC1α expression is reduced in PKD animals, which is attenuated by short salsalate treatment. (E) Western blotting for pS6, S6, and p-p70S6K on protein extracts isolated from wildtype, PKD, and PKD + SAL kidneys. β-actin and tubulin protein expression were used as an internal loading control. (F) Quantification of the pS6, S6, and p-p70S6K blots shown in (E), relative to β-actin (pS6, S6) and tubulin (p-p70S6K). No significant differences were detected between wildtype, PKD, and PKD + SAL animals. Each dot represents a mouse kidney (n = 3–4 animals per group). Data presented are mean ± SD. ∗p < 0.05, ∗∗p < 0.01, measured by two-way unpaired Student’s t tests. M = marker, MW = molecular weight, WT = wildtype, SAL = Salsalate, kDa = kilodalton.

    Article Snippet: Rabbit anti-pS6 primary antibody , Cell Signaling , 2215; RRID: AB_331682.

    Techniques: Western Blot, Isolation, Expressing, Control, Marker, Molecular Weight

    Journal: iScience

    Article Title: Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease

    doi: 10.1016/j.isci.2023.108278

    Figure Lengend Snippet:

    Article Snippet: Rabbit anti-pS6 primary antibody , Cell Signaling , 2215; RRID: AB_331682.

    Techniques: Recombinant, SYBR Green Assay, Protease Inhibitor, Blocking Assay, cDNA Synthesis, Software, Gene Expression, Magnetic Beads

    a . Comparison of feature embedding methodologies (CP-DINO 1640 with and without pS6 information) based on median AUC of binary classification of KO from WT for each genetic perturbation. b . Top neighbor genes to mTOR and TSC2 (mTORC1 activator and inhibitor respectively) predicted with and without pS6 are shown. Numbers indicate cosine similarity. c . the pipeline for conducting single-cell based analysis via Kolmogorov-Smirnov 2-sided, 2-tailed statistical test with benjamini-hochberg correction, in contrast to methods used for flow-based screens such as MAUDE . d . results of single-cell based, one-feature analysis of cytoplasmic phospho-S6. Teal genes are well established mTOR upregulators, orange genes are well established mTOR downregulators, black genes are potentially novel pS6 modifiers. e . representative pS6 field with segmentation. f . example pS6 and mitoprobe staining images from control, known, and potentially novel regulators of mTORC1. g-h . differential feature analysis on AURKAIP1 and HSD17B10 .

    Journal: bioRxiv

    Article Title: A Pooled Cell Painting CRISPR Screening Platform Enables de novo Inference of Gene Function by Self-supervised Deep Learning

    doi: 10.1101/2023.08.13.553051

    Figure Lengend Snippet: a . Comparison of feature embedding methodologies (CP-DINO 1640 with and without pS6 information) based on median AUC of binary classification of KO from WT for each genetic perturbation. b . Top neighbor genes to mTOR and TSC2 (mTORC1 activator and inhibitor respectively) predicted with and without pS6 are shown. Numbers indicate cosine similarity. c . the pipeline for conducting single-cell based analysis via Kolmogorov-Smirnov 2-sided, 2-tailed statistical test with benjamini-hochberg correction, in contrast to methods used for flow-based screens such as MAUDE . d . results of single-cell based, one-feature analysis of cytoplasmic phospho-S6. Teal genes are well established mTOR upregulators, orange genes are well established mTOR downregulators, black genes are potentially novel pS6 modifiers. e . representative pS6 field with segmentation. f . example pS6 and mitoprobe staining images from control, known, and potentially novel regulators of mTORC1. g-h . differential feature analysis on AURKAIP1 and HSD17B10 .

    Article Snippet: Rabbit anti-human pS6 primary antibody (Cell Signaling Technologies, 2215S) solution was made by diluting pS6 primary Ab 1:250 in antibody buffer solution.

    Techniques: Comparison, Staining, Control

    a-b. the pipeline and results for simulated pseudo binned FACS data, using MAUDE to predict the likely shift in mean cytoplasmic phospho-S6 caused by each gene’s regulation. While some shifting in order occurred, this analysis resulted in similar top-ranked genes to when the data is analyzed using single cell information. c. differential feature analysis on MRPS5 .

    Journal: bioRxiv

    Article Title: A Pooled Cell Painting CRISPR Screening Platform Enables de novo Inference of Gene Function by Self-supervised Deep Learning

    doi: 10.1101/2023.08.13.553051

    Figure Lengend Snippet: a-b. the pipeline and results for simulated pseudo binned FACS data, using MAUDE to predict the likely shift in mean cytoplasmic phospho-S6 caused by each gene’s regulation. While some shifting in order occurred, this analysis resulted in similar top-ranked genes to when the data is analyzed using single cell information. c. differential feature analysis on MRPS5 .

    Article Snippet: Rabbit anti-human pS6 primary antibody (Cell Signaling Technologies, 2215S) solution was made by diluting pS6 primary Ab 1:250 in antibody buffer solution.

    Techniques: